Literature DB >> 28114590

Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.

Masayuki Hata1, Kenji Yamashiro1, Sotaro Ooto1, Akio Oishi1, Hiroshi Tamura1, Manabu Miyata1, Naoko Ueda-Arakawa1, Ayako Takahashi1, Akitaka Tsujikawa2, Nagahisa Yoshimura1.   

Abstract

Purpose: To investigate the difference in intraocular vascular endothelial growth factor (VEGF) concentration between pachychoroid neovasculopathy and neovascular age-related macular degeneration (nAMD) and its associations with responses to three monthly anti-VEGF injections as an initial treatment for the two conditions.
Methods: This study included nine eyes with treatment-naïve pachychoroid neovasculopathy and 21 eyes with treatment-naïve nAMD. Before the initial intravitreal anti-VEGF injection, aqueous humor samples were collected and the concentration of VEGF was measured using enzyme-linked immunosorbent assay. The concentration was compared between the two conditions, and its associations with responses to anti-VEGF therapy were investigated.
Results: The mean VEGF concentration in pachychoroid neovasculopathy was significantly lower than that in nAMD (63.4 ± 17.8 pg/ml and 89.8 ± 45.0 pg/ml, respectively; P = 0.035). The VEGF concentration was associated with the presence or absence of drusen (β = 0.503, P = 0.004). After anti-VEGF therapy, 6 (66.7%) of 9 eyes with pachychoroid neovasculopathy and 17 (81.0%) of 21 eyes with nAMD achieved dry macula (P = 0.640). Dry macula at 3 months and 12 months was significantly associated with a low VEGF concentration in pachychoroid neovasculopathy (P = 0.013 and P = 0.042, respectively), but not in nAMD (P = 0.108 and P = 0.219). Conclusions: The mean VEGF concentration in pachychoroid neovasculopathy was lower than that in nAMD, suggesting that the way in which VEGF is involved in angiogenesis may differ between pachychoroid neovasculopathy and nAMD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28114590     DOI: 10.1167/iovs.16-20967

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  33 in total

1.  AREDS simplified severity scale as a predictive factor for response to aflibercept therapy for typical neovascular age-related macular degeneration.

Authors:  Yoichi Sakurada; Wataru Kikushima; Atsushi Sugiyama; Seigo Yoneyama; Naohiko Tanabe; Mio Matsubara; Hiroyuki Iijima
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-24       Impact factor: 3.117

Review 2.  Pachychoroid neovasculopathy: a type-1 choroidal neovascularization belonging to the pachychoroid spectrum-pathogenesis, imaging and available treatment options.

Authors:  Francesco Sartini; Michele Figus; Giamberto Casini; Marco Nardi; Chiara Posarelli
Journal:  Int Ophthalmol       Date:  2020-07-30       Impact factor: 2.031

Review 3.  Choroidal imaging using optical coherence tomography: techniques and interpretations.

Authors:  Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2022-02-16       Impact factor: 2.447

4.  One-year outcomes of half-fluence photodynamic therapy combined with intravitreal injection of aflibercept for pachychoroid neovasculopathy without polypoidal lesions.

Authors:  Hidetaka Matsumoto; Ryo Mukai; Yuka Kikuchi; Masahiro Morimoto; Hideo Akiyama
Journal:  Jpn J Ophthalmol       Date:  2020-02-03       Impact factor: 2.447

5.  The use of optical coherence tomography angiography in pachychoroid spectrum diseases: a concurrent comparison with dye angiography.

Authors:  Sibel Demirel; Özge Yanık; Hilal Nalcı; Figen Batıoğlu; Emin Özmert
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-09-11       Impact factor: 3.117

6.  Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents.

Authors:  Benedikt Schworm; Nikolaus Luft; Leonie F Keidel; Felix Hagenau; Christoph Kern; Tina Herold; Karsten U Kortuem; Siegfried G Priglinger; Jakob Siedlecki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-02-28       Impact factor: 3.117

7.  Efficacy of treat-and-extend regimen with aflibercept for pachychoroid neovasculopathy and Type 1 neovascular age-related macular degeneration.

Authors:  Hidetaka Matsumoto; Takashi Hiroe; Masahiro Morimoto; Kensuke Mimura; Arisa Ito; Hideo Akiyama
Journal:  Jpn J Ophthalmol       Date:  2018-02-06       Impact factor: 2.447

8.  Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy.

Authors:  Jihyun Yoon; Wontae Yoon; Seung Kwan Na; Jihyun Lee; Chul Gu Kim; Jong Woo Kim; Han Joo Cho
Journal:  Sci Rep       Date:  2021-06-08       Impact factor: 4.379

Review 9.  Pachychoroid disease.

Authors:  Chui Ming Gemmy Cheung; Won Ki Lee; Hideki Koizumi; Kunal Dansingani; Timothy Y Y Lai; K Bailey Freund
Journal:  Eye (Lond)       Date:  2018-07-11       Impact factor: 3.775

10.  Two-Thirds Dose Photodynamic Therapy for Pachychoroid Neovasculopathy.

Authors:  Koji Tanaka; Ryusaburo Mori; Yu Wakatsuki; Hajime Onoe; Akiyuki Kawamura; Hiroyuki Nakashizuka
Journal:  J Clin Med       Date:  2021-05-17       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.